(NASDAQ: NAMS) Newamsterdam Pharma Co Nv's forecast annual revenue growth rate of 241.14% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Newamsterdam Pharma Co Nv's revenue in 2026 is $8,232,369.On average, 19 Wall Street analysts forecast NAMS's revenue for 2026 to be $3,733,026,251, with the lowest NAMS revenue forecast at $784,881,052, and the highest NAMS revenue forecast at $7,530,841,647. On average, 18 Wall Street analysts forecast NAMS's revenue for 2027 to be $15,042,557,347, with the lowest NAMS revenue forecast at $1,171,464,256, and the highest NAMS revenue forecast at $49,515,881,515.
In 2028, NAMS is forecast to generate $41,961,132,434 in revenue, with the lowest revenue forecast at $15,111,888,905 and the highest revenue forecast at $124,557,730,098.